What happened

The US government has announced up to $4.9 million to prepare research into ibogaine as a possible treatment for post-traumatic stress disorder and other serious mental illnesses. Health Secretary Robert F. Kennedy Jr. announced the funding on Thursday, alongside Veterans Affairs Secretary Doug Collins.S1R1

The commitment runs over five years through the Advanced Research Projects Agency for Health, known as ARPA-H. The agency says payments depend on research teams reaching milestones. HHS says this award supports regulatory and manufacturing preparations: it does not fund patient treatment or human-subject research, authorise clinical trials or establish FDA approval.R1R2

Why it matters

Ibogaine is derived from a West African shrub and can produce intense hallucinations. The Associated Press reports that adverse effects can include nausea, vomiting and tremors, alongside potentially fatal irregular heart rhythms. HHS also identifies serious cardiac risks and says potential benefits still require rigorous evaluation.S1R1

Advocates, including veterans' organisations, argue that the drug could help people with conditions that have resisted existing treatments. Those claims are part of the case for studying it, rather than results established by this funding announcement. Collins said the effort would put safety and high-quality research first.S1

The background

ARPA-H has selected teams led by Beond and Mark Cuban Cost Plus Drug Company. Beond's role concerns clinical data, while the other team will develop foundations for a domestically manufactured ibogaine hydrochloride product. Both projects are intended to support further development rather than supply an approved medicine.R1R2

Kennedy said the government would receive data and treatment guidance from Beond, which has treated patients in Mexico. Much of the existing evidence comes from people seeking treatment abroad, according to the Associated Press. Experience at overseas clinics does not itself settle the questions US regulators are considering about safety and effectiveness.S1R3

The announcement follows President Donald Trump's April directive to accelerate psychedelic research. In October, the FDA sought information on the design of early ibogaine trials, including eligibility, safety monitoring and independent oversight. The regulator highlighted scientific uncertainties and serious safety concerns.S1R3

What happens next

Kennedy predicted an unusually rapid approval process, but that remains his expectation. The award does not set an approval date or establish that the drug will receive approval. HHS says further awards are expected to examine its potential for substance use disorders.S1R1

The FDA's consultation closes on 20 November. Meanwhile, HHS says findings will be made public whether they show benefit, no benefit or harm, with patient privacy protected. Research outcomes therefore remain open, despite officials' stated hopes for the treatment.R1R3